what was the first glp 1 Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1 | Pancreapedia

This week, we will discuss the blockbuster trial of 2024, FLOW

Nausea affects up to 40% of GLP-1 users during initial treatment, but simple dietary and lifestyle adjustments can significantly reduce discomfort

Physiological Effects Semaglutide exerts its therapeutic benefits through multiple complementary mechanisms: Enhanced Insulin Secretion: Stimulates glucose-dependent insulin release from pancreatic beta cells, improving postprandial glucose control[3][4] Glucagon Suppression: Inhibits glucagon release, reducing hepatic glucose production and improving fasting blood glucose levels[3][4] Delayed Gastric Emptying: Slows the movement of food from the stomach to the small intestine, reducing postprandial glucose excursions and promoting satiety[4][5] Appetite Reduction: Directly affects the central nervous system to decrease food intake and energy consumption[4][5] Improved Metabolic Flexibility: Enhances the body's ability to switch between energy substrates based on availability[2] At the cellular level, semaglutide primarily operates through the AMPK (AMP-activated protein kinase) pathway, which regulates cellular energy homeostasis and improves insulin sensitivity

Shapely is in-network with Humana for weight loss treatment

Tirzepatide affects levothyroxine absorption through delayed gastric emptying

A Northeastern pharmacy professor explains why low cost weight loss drugs like compounded semaglutide are disappearing.